<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352466</url>
  </required_header>
  <id_info>
    <org_study_id>ALT201-101</org_study_id>
    <nct_id>NCT03352466</nct_id>
  </id_info>
  <brief_title>NasoShield Study of Safety and Immunogenicity</brief_title>
  <acronym>NasoShield</acronym>
  <official_title>First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation&#xD;
      clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18&#xD;
      to 49 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation&#xD;
      clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18&#xD;
      to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1). The&#xD;
      study is comprised of 2 parts:&#xD;
&#xD;
        -  Part A: Approximately 120 subjects who meet all inclusion and no exclusion criteria and&#xD;
           provide written informed consent will be enrolled into 4 sequential cohorts of 30&#xD;
           subjects each defined by the NasoShield dose (1×108, 1×109, 1×1010, and 1×1011 vp).&#xD;
           Within each cohort (and the sentinel group in the first dose cohort), subjects will be&#xD;
           randomized in a 4:1:1 ratio to receive 1 intranasal dose of NasoShield (Day 1), 1&#xD;
           intranasal dose of placebo (Day 1), or 3 subcutaneous 0.5 mL doses of BioThrax 14 days&#xD;
           apart (Days 1, 15, and 29). NasoShield and placebo will be administered in a&#xD;
           double-blind fashion, and BioThrax will be administered in an open-label fashion.&#xD;
&#xD;
        -  Part B: Approximately 25 subjects who meet all inclusion and no exclusion criteria and&#xD;
           provide written informed consent will be randomized in a 4:1 fashion to receive 2&#xD;
           intranasal doses of NasoShield at the highest well tolerated dose from Part A or placebo&#xD;
           21 days apart (Days 1 and 22). NasoShield and placebo will be administered in a&#xD;
           double-blind fashion.&#xD;
&#xD;
      Subjects will return to the investigational site for multiple visits through Day 361. At each&#xD;
      visit, the subject will be asked about the interim medical history and use of any&#xD;
      medications, and safety and immunogenicity assessments will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 3, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>For 14 days after vaccination</time_frame>
    <description>Subjects will record solicited local and systemic events for 14 days after each dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>All adverse events from Day 1 to Day 57, SAEs, medically attended AEs and new onset chronic illnesses Day 1 to Day 361</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-PA immunoglobulin G (IgG)</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>Titer measured by enzyme-linked immunosorbent assay (ELISA) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxin neutralization assay (TNA)</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>50% neutralization factor (NF50) titer measured by cytotoxic assay in serum</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>NasoShield very low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal spray (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal spray (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal spray (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioThrax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three intramuscular injections 15 days apart (Part A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NasoShield</intervention_name>
    <description>NasoShield is an adenovirus-vectored anthrax vaccine.</description>
    <arm_group_label>NasoShield high dose</arm_group_label>
    <arm_group_label>NasoShield low dose</arm_group_label>
    <arm_group_label>NasoShield medium dose</arm_group_label>
    <arm_group_label>NasoShield very low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BioThrax</intervention_name>
    <description>Commercially available anthrax vaccine</description>
    <arm_group_label>BioThrax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women 18 to 49 years of age, inclusive&#xD;
&#xD;
          2. Good general health status as determined by the Investigator&#xD;
&#xD;
          3. Adequate venous access for repeated phlebotomies&#xD;
&#xD;
          4. Screening laboratory results within institutional normal range or Grade 1 abnormality&#xD;
             if the Investigator documents clinical insignificance. Creatine kinase or bilirubin&#xD;
             may be Grade 2 if associated with normal alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) and the Investigator considers the result not to be clinically&#xD;
             significant due to vigorous exercise or Gilbert's syndrome&#xD;
&#xD;
          5. Negative drug and alcohol screen at Screening and predose on Day 1&#xD;
&#xD;
          6. For women who have not been surgically sterilized and do not have laboratory&#xD;
             confirmation of postmenopausal status, negative pregnancy test&#xD;
&#xD;
          7. Willingness to practice a highly effective method of contraception: abstinence, sex&#xD;
             only with persons of the same sex, monogamous relationship with a postmenopausal&#xD;
             partner, monogamous relationship with vasectomized partner, vasectomy, surgical&#xD;
             sterilization (hysterectomy, bilateral tubal ligation, salpingectomy, or&#xD;
             oophorectomy), licensed hormonal methods, intrauterine device (IUD), or consistent use&#xD;
             of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last&#xD;
             IP dose&#xD;
&#xD;
          8. Willingness to participate and comply with all aspects of the study through the entire&#xD;
             study period, including nasopharyngeal swabs and blood and urine samples&#xD;
&#xD;
          9. Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Pregnant, possibly pregnant, or lactating women&#xD;
&#xD;
          2. Household contacts of pregnant women, children &lt; 5 years of age, or immunocompromised&#xD;
             individuals for the period up through 2 weeks postvaccination&#xD;
&#xD;
          3. Persons who care for pregnant women, children &lt; 5 years of age, or immunocompromised&#xD;
             individuals for the period up through 2 weeks postvaccination&#xD;
&#xD;
          4. Body mass index &gt; 35.0 kg/m2&#xD;
&#xD;
          5. Positive result for HIV, hepatitis B virus, or hepatitis C virus at Screening&#xD;
&#xD;
          6. Asthma or other chronic lung disease that is greater than mild in severity.&#xD;
             Specifically excluded are participants with any of the following events in the past&#xD;
             year:&#xD;
&#xD;
               -  Daily symptoms&#xD;
&#xD;
               -  Daily use of short acting beta 2 agonists&#xD;
&#xD;
               -  Use of inhaled steroids or theophylline&#xD;
&#xD;
               -  Use of pulse systemic steroids&#xD;
&#xD;
               -  Emergency care or hospitalization related to asthma or other chronic lung disease&#xD;
&#xD;
               -  Systemic steroids for asthma exacerbation&#xD;
&#xD;
          7. History of diabetes mellitus (gestational diabetes is allowed if treatment was not&#xD;
             required postpartum and serum glucose is currently in the normal range)&#xD;
&#xD;
          8. History of coronary artery disease, arrhythmia, or congestive heart failure&#xD;
&#xD;
          9. Clinically significant ECG abnormality as determined by the Investigator&#xD;
&#xD;
         10. Poorly controlled hypertension (systolic blood pressure &gt; 150 mmHg or diastolic blood&#xD;
             pressure &gt; 95 mmHg) at Screening or predose on Day 1&#xD;
&#xD;
         11. History of anaphylaxis or angioedema&#xD;
&#xD;
         12. Known allergy to any of the ingredients in the vaccine formulation&#xD;
&#xD;
         13. Known allergy or sensitivity to latex&#xD;
&#xD;
         14. History of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other&#xD;
             nasal abnormality that might affect vaccine administration&#xD;
&#xD;
         15. Previous nasal surgery or nasal cauterization&#xD;
&#xD;
         16. Any symptoms of upper respiratory infection or temperature &gt; 38°C within 3 days before&#xD;
             Day 1&#xD;
&#xD;
         17. Any symptoms within 24 hours before Day 1 of upper respiratory illness or allergy&#xD;
             flare-up that, in the opinion of the Investigator, presents as nasal congestion or&#xD;
             rhinorrhea that could inhibit the proper administration of the IP&#xD;
&#xD;
         18. Known or suspected malignancy, excluding non-melanoma skin cancers and other early&#xD;
             stage surgically excised malignancies that the Investigator considers to be&#xD;
             exceedingly unlikely to recur&#xD;
&#xD;
         19. Immunocompromised individuals, including those who have used corticosteroids&#xD;
             (including intranasal steroids), alkylating drugs, antimetabolites, radiation,&#xD;
             immune-modulating biologics, or other immunomodulating therapies within 90 days before&#xD;
             Day 1 or those who plan use during the study period&#xD;
&#xD;
         20. Use of statin medication within 30 days before Day 1 (see list in Section 6.8.1)&#xD;
&#xD;
         21. Receipt of intranasal medications (including over-the-counter medications) within 30&#xD;
             days before Day 1&#xD;
&#xD;
         22. Receipt of any IP within 30 days before Day 1&#xD;
&#xD;
         23. Receipt of any vaccine within 30 days before Day 1&#xD;
&#xD;
         24. Receipt of intranasal vaccine within 90 days before Day 1&#xD;
&#xD;
         25. Receipt of any licensed or investigational anthrax vaccine&#xD;
&#xD;
         26. Any change in medication for a chronic medical condition within 30 days before Day 1&#xD;
&#xD;
         27. Past regular use or current use of intranasal illicit drugs&#xD;
&#xD;
         28. Smokers, including smoking of any type (eg, cigarettes, electronic cigarettes,&#xD;
             marijuana). Prior smokers must have quit smoking at least 30 days before Day 1.&#xD;
&#xD;
         29. Any medical, psychiatric, or social condition or occupational or other responsibility&#xD;
             that in the judgment of the Investigator would interfere with or serve as a&#xD;
             contraindication to protocol adherence, assessment of safety (including&#xD;
             reactogenicity), or a subject's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuel DeNoia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON plc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anthrax</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

